4//SEC Filing
Alenson Carman 4
Accession 0001894562-25-000042
CIK 0001894562other
Filed
Aug 4, 8:00 PM ET
Accepted
Aug 5, 8:42 PM ET
Size
416.6 KB
Accession
0001894562-25-000042
Insider Transaction Report
Form 4
Alenson Carman
See Remarks
Transactions
- Award
Stock Option (right to buy)
2025-08-01+16,083→ 16,083 totalExercise: $4.04Exp: 2032-01-24→ Common Stock (16,083 underlying) - Award
Stock Option (right to buy)
2025-08-01+90,498→ 90,498 totalExercise: $4.04Exp: 2034-02-21→ Common Stock (90,498 underlying) - Award
Stock Option (right to buy)
2025-08-01+90,498→ 90,498 totalExercise: $4.04Exp: 2033-03-31→ Common Stock (90,498 underlying) - Disposition to Issuer
Stock Option (right to buy)
2025-08-01−90,498→ 0 totalExercise: $8.49Exp: 2034-02-21→ Common Stock (90,498 underlying) - Disposition to Issuer
Stock Option (right to buy)
2025-08-01−16,083→ 0 totalExercise: $10.92Exp: 2032-01-24→ Common Stock (16,083 underlying) - Disposition to Issuer
Stock Option (right to buy)
2025-08-01−90,498→ 0 totalExercise: $12.30Exp: 2033-03-31→ Common Stock (90,498 underlying) - Disposition to Issuer
Stock Option (right to buy)
2025-08-01−6,254→ 0 totalExercise: $13.63Exp: 2033-04-18→ Common Stock (6,254 underlying) - Award
Stock Option (right to buy)
2025-08-01+6,254→ 6,254 totalExercise: $4.04Exp: 2033-04-18→ Common Stock (6,254 underlying)
Footnotes (2)
- [F1]Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.
- [F2]This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
Issuer
Prime Medicine, Inc.
CIK 0001894562
Entity typeother
Related Parties
1- filerCIK 0001688865
Filing Metadata
- Form type
- 4
- Filed
- Aug 4, 8:00 PM ET
- Accepted
- Aug 5, 8:42 PM ET
- Size
- 416.6 KB